Gambro Lundia

Disposable set and extracorporeal blood treatment apparatus comprising a blood circuit including a filtration unit, a blood withdrawal line, a blood return line, a blood pump tract on the blood withdrawal line or on the blood return line and configured to be engaged to a blood pump of the extracorporeal blood treatment apparatus to promote blood flow in the blood circuit. The blood circuit further comprises an infusion connected to both the blood withdrawal line at a first site, and to the return line at a second site. The blood circuit is configurable in a loop recirculation circuit including the filtration unit, the blood pump tract, a part of the blood withdrawal line, a part of the blood return line and a recirculation portion of the infusion line interposed between the first site and the second site.

The invention relates to a blood treatment device configured to dephosphorylate extracellular adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and/or lipopolysaccharide (LPS) in the blood of a patient in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix having alkaline phosphatase (AP) immobilized thereon. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device of the invention and to the blood treatment device for use as a medicament or to methods of treating an infection, preferably a blood or systemic infection, such as sepsis, and/or for the treatment of sepsis-associated acute kidney injury (AKI).

The invention relates to a whole blood compatible matrix for coupling a ligand and use in extracorporeal blood treatment, said matrix comprising a solid substrate, said substrate comprising a first layer of polyethylene glycol (PEG) and at least a second layer of polyethylene glycol, wherein said at least second layer is positioned outside the first layer and is bound to said first layer, and wherein the polyethylene glycol of the at least second layer comprises a terminal functional group for coupling said ligand to said polyethylene glycol. The invention further relates to a blood treatment device in the form of an adsorption cartridge or column, comprising the matrix according to the present invention, wherein the matrix is whole blood compatible. The invention further relates to the matrix of the invention comprising a ligand coupled thereto (apheresis matrix). The invention further relates to a method of preparing an apheresis matrix, comprising coupling the polyethylene glycol of the at least second layer of the matrix to the ligand. The invention further relates to a ligand coupled to the polyethylene glycol of the apheresis matrix according to the invention for use in the treatment of a medical condition by extracorporeal blood treatment.

The invention relates to a whole-blood compatible matrix for coupling a ligand and use in extracorporeal blood treatment, comprising a solid substrate having bound thereon polyethylene glycol (PEG), wherein the solid substrate comprises particles, wherein said particles have: a diameter of about 100 µm to about 1000 µm and an average pore size of about 20 nm to about 300 nm, the polyethylene glycol has a molecular weight of about 500 - 7000 Daltons, and wherein the polyethylene glycol comprises a terminal functional group for coupling the ligand to said polyethylene glycol, and wherein the polyethylene glycol is liner, Y-shaped, or branched. The invention further relates to a blood treatment device in the form of an adsorption cartridge or column, comprising the matrix according to the present invention. The invention further relates to a ligand coupled to the polyethylene glycol of the matrix according to the invention for use in the treatment of a medical condition by extracorporeal blood treatment.

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

Zusammenfassung wird geladen …

A control unit of an apparatus for extracorporeal blood treatment is configured to perform a control procedure comprising: calculating parameter control values to be set during a time interval after the instant in which the control is made, on the basis of actual values and of prescription values of variation in blood volume, ultrafiltration flow rate, concentration of sodium; imposing the parameter control values during the time interval consecutive to the instant in which the control is made such that the actual values of the variation in blood volume track the prescription values of the variation in blood volume over a predetermined treatment time. The control unit is further configured to perform a procedure for automatically estimating/calculating a target plasma conductivity and/or a target concentration of sodium in plasma to be reached at the end of the extracorporeal blood treatment.

Zusammenfassung wird geladen …